Thanh bên bài viết

PDF
Ngày xuất bản: 31/07/2025
Ngày xuất bản Online: 10/07/2025
Số lượt xem tóm tắt: 12
Số lượt xem PDF: 5
DOI: https://doi.org/10.47972/vjcts.v51i.1380
Số xuất bản
Tập 51
Chuyên mục
Bài báo
Trích dẫn bài báo
Nguyen, N. T., Nguyen, V. T., Nguyen, S. H., & Tran, T. H. (2025). A case report: catecholamine-secreting adrenal tumor-inducing cardiomyopathy. Tạp chí Phẫu thuật Tim mạch và Lồng ngực Việt Nam, 51, 67 - 74. https://doi.org/10.47972/vjcts.v51i.1380

A case report: catecholamine-secreting adrenal tumor-inducing cardiomyopathy

Nguyen Ngoc Tan1, Nguyen Van Thuc1, Nguyen Sinh Hien1, Tran Thanh Hoa1,
1 Hanoi Heart Hospital

Nội dung chính của bài viết

Tóm tắt

Introduction: Catecholamine-secreting adrenal tumors (pheochromocytoma/paraganglioma) are rare neoplasms causing paroxysmal hypertension, metabolic disturbances, and cardiomyopathy. Diagnosis relies on biochemical tests (plasma-free metanephrines) and imaging (CT/MRI). Definitive treatment involves tumor resection with perioperative hemodynamic control.


Case summary: A 47-year-old female with no prior hypertension presented with chest pain, hypertensive crisis (180/100 mmHg), hyperglycemia, and metabolic acidosis. Elevated norepinephrine (312.33 pg/mL) and abdominal MRI confirmed a right adrenal tumor (22×22×20 mm). A surgical resection was performed. Postoperatively, blood pressure normalized, and cardiac function improved (EF increased from 47% to 70% at the 2-month follow-up).


Conclusion: Catecholamine-secreting tumors may induce severe cardiomyopathy even without a hypertension history. Early diagnosis and prompt surgery are critical for cardiac recovery and preventing complications.

Chi tiết bài viết

Từ khóa

Adrenal tumor, catecholamine, cardiomyopathy, pheochromocytoma

Tài liệu tham khảo

[1] Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG, Murad MH, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2014 Jun 1;99(6):1915–42.
[2] Lenders JWM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005 Aug 20;366(9486):665–75.
[3] Mannelli M. Management and Treatment of Pheochromocytomas and Paragangliomas. Annals of the New York Academy of Sciences. 2006;1073(1):405–16.
[4] Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, et al. Pheochromocytoma: current approaches and future directions. Oncologist. 2008 Jul;13(7):779–93.
[5] Alderazi Y, Yeh MW, Robinson BG, Benn DE, Sywak MS, Learoyd DL, et al. Phaeochromocytoma: current concepts. Med J Aust [Internet]. 2005 Aug 15 [cited 2025 May 21];183(4). Available from: https://www.mja.com.au/journal/2005/183/4/phaeochromocytoma-current-concepts
[6] Lenders JWM, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002 Mar 20;287(11):1427–34.
[7] Sawka AM, Jaeschke R, Singh RJ, Young WF. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003 Feb;88(2):553–8.
[8] Sawka AM, Prebtani AP, Thabane L, Gafni A, Levine M, Young WF. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr Disord. 2004 Jun 29;4(1):2.
[9] Eisenhofer G, Pamporaki C, Lenders JWM. Biochemical Assessment of Pheochromocytoma and Paraganglioma. Endocr Rev. 2023 Sep 15;44(5):862–909.
[10] Farrugia FA, Martikos G, Tzanetis P, Charalampopoulos A, Misiakos E, Zavras N, et al. Pheochromocytoma, diagnosis and treatment: Review of the literature. Endocr Regul. 2017 Jul 1;51(3):168–81.
[11] Carrasquillo JA, Chen CC, Jha A, Ling A, Lin FI, Pryma DA, et al. Imaging of Pheochromocytoma and Paraganglioma. J Nucl Med. 2021 Aug 1;62(8):1033–42.
[12] Neumann HPH, Young WF, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019 Aug 8;381(6):552–65.
[13] Shulkin BL, Ilias I, Sisson JC, Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci. 2006 Aug;1073:374–82.
[14] Esfandiari NH, Shulkin BL, Bui C, Jaffe CA. Multimodality imaging of malignant pheochromocytoma. Clin Nucl Med. 2006 Dec;31(12):822–5.
[15] Gumbs AA, Gagner M. Laparoscopic adrenalectomy. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):483–99.
[16] Soon PSH, Yeh MW, Delbridge LW, Bambach CP, Sywak MS, Robinson BG, et al. Laparoscopic surgery is safe for large adrenal lesions. Eur J Surg Oncol. 2008 Jan;34(1):67–70.
[17] Recurrent Catecholamine-Induced Cardiomyopathy and Hypertensive Emergencies: A presentation of Pheochromocytoma and Related Concerns - PubMed [Internet]. [cited 2025 May 21]. Available from: https://pubmed.ncbi.nlm.nih.gov/32135056/
[18] Diaz B, Elkbuli A, Ehrhardt JD, McKenney M, Boneva D, Hai S. Pheochromocytoma-related cardiomyopathy presenting as broken heart syndrome: Case report and literature review. Int J Surg Case Rep. 2019;55:7–10.
[19] Santos JRU, Brofferio A, Viana B, Pacak K. Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease? Horm Metab Res. 2019 Jul;51(7):458–69.
[20] Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses?: A Systematic Analytical Review. - AMiner [Internet]. [cited 2025 May 21]. Available from: https://www.aminer.cn/pub/56d8de9bdabfae2eee036493/acute-and-chronic-pheochromocytoma-induced-cardiomyopathies-different-prognoses-a-systematic-analytical-review?source=zz1
[21] Choi SY, Cho KI, Han YJ, You GI, Kim JH, Heo JH, et al. Impact of Pheochromocytoma on Left Ventricular Hypertrophy and QTc Prolongation: Comparison with Takotsubo Cardiomyopathy. Korean Circ J. 2014 Mar;44(2):89–96.
[22] Martucci VL, Pacak K. Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, Management, and Treatment. Curr Probl Cancer. 2014;38(1):7–41.
[23] Mazza A, Armigliato M, Marzola MC, Schiavon L, Montemurro D, Vescovo G, et al. Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. Endocrine. 2014 Apr;45(3):469–78.
[24] Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007 Nov;92(11):4069–79.